Avoidance of dental care because of dental anxiety often result in reduced dental health and need for sedation or treatment in general anesthesia. Treatment of dental anxiety is time consuming and not given priority. D-cycloserine has shown to increase the effectiveness of the anxiety/ phobia treatment among adults, but needs to be tested among younger age groups. A medication that will enhance the effect of the anxiety treatment would be of great advantage for the fearful young patient.
Conditions
Interventions
Trade Name: Seromycin (Cycloserine Capsules, USP).
Product Name: D-Cycloserine
Pharmaceutical Form: Capsule*
Sponsors
University of Oslo, Institute of Clinical Dentistry
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • Persons of both sexes (ASA type I). • Persons under no other medicational treatment • Age 12 to 18 years • Not able to receive ordinary dental treatment because of dental anxiety and/ or intra-oral injection phobia Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: • Hypersensitivity to cycloserine • Epilepsi • Renal insufficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The research is a pilot study where the major aim is to get more experience with the combination of brief CBT and low-dose of DCS used in children and adolescents ;Secondary Objective: To develop and pilot test a protocol (procedure and instruments) for planning of a future randomized clinical trial in children and adolescents to test the effectiveness of a combination of cognitive behavior therapy and D-cycloserine among younger age groups.;Primary end point(s): Changes in self-reports of dental anxiety and positive and negative thoughts during dental treatment. | — |
Countries
Norway
Outcome results
None listed